ArticleCureus2026
No Surprises Act Independent Dispute Resolution: A Five-Gate Evidentiary Framework for Evaluating Reform Claims.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe No Surprises Act (NSA) removes patients from many out-of-network payment disputes. Debate continues over whether the Federal Independent Dispute Resolution (IDR) process is being abused and should be restricted or rebenchmarked. We evaluate whether commonly cited Federal IDR statistics support the policy inferences drawn from them.
methodsWe apply a five-gate evidentiary framework (examining the Denominator, Comparator, Selection, Causation, and Attribution) to 12 recurring Federal IDR reform claims using statutory, regulatory, judicial, federal, and published sources. We supplement this framework with a line-item analysis of Centers for Medicare & Medicaid Services (CMS) Federal IDR public-use files for the first half of 2025.
resultsFederal IDR utilization greatly exceeds the original forecast of 22,232 disputes annually. CMS reports 6,336,032 disputes initiated through May 2026, of which 1,066,645 (16.83%) are found ineligible. Challenge rates represent a distinct and materially higher quantity, running approximately 40%-42% across individual CMS reporting periods, each with its own denominator. CMS reports that providers prevail in 87% of non-default, fully contested determinations in the first half of 2025. Among 1,694,788 analyzed line items, providers prevail in 1,476,967 (87.15%), and 1,446,720 (97.95%) of provider-prevailing line items have payments above the Qualifying Payment Amount (QPA). Among these same line items, however, 97.67% of all provider offers exceed QPA regardless of outcome, indicating that the observed coupling between provider victory and above-QPA payment is substantially consistent with the underlying positioning of provider offers. This observation does not explain the underlying win-rate asymmetry. The primary specification showed little evidence of a material residual association after stratification (Mantel-Haenszel odds ratio (OR) 1.0064, 95% cluster-bootstrap confidence interval (CI) 0.973-1.045; 2,000 replicates), as did a wider sensitivity specification (OR 0.9948, 95% CI 0.961-1.032). An exact-QPA post-hoc sensitivity specification showed a small positive association (OR 1.0367, 95% CI 1.002-1.080). Because multiple related sensitivity specifications were examined without multiplicity adjustment, this marginal estimate is exploratory rather than confirmatory. The cause of the overall adjudicatory asymmetry remains unresolved.
conclusionsThe examined statistics establish substantial Federal IDR utilization, ineligibility, filing concentration, adjudicatory asymmetry, and payment divergence from QPA, but do not independently establish provider abuse, benchmark validity, network erosion, price or premium inflation, or incremental arbitration cost. Applied symmetrically, the same evidentiary standard that prevents provider win rates from proving provider virtue also prevents those rates from proving provider abuse. Policy decisions increasing QPA's determinative role require evidence capable of distinguishing case selection, payer behavior, benchmark performance, statutory factors, and adjudicatory effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.